Literature DB >> 1578449

Transverse myelitis in systemic lupus erythematosus--the effect of IV pulse methylprednisolone and cyclophosphamide.

L Barile1, C Lavalle.   

Abstract

Transverse myelitis is a rare but serious complication of systemic lupus erythematosus (SLE). Standard treatment with medium to high doses of oral prednisone has been inadequate to control neurologic sequelae, and patients remain confined to a wheel chair or even die. We employed aggressive treatment in 7 patients with transverse myelitis complicating SLE with pulse methylprednisolone for acute episodes followed by pulse cyclophosphamide for a mean of 6 months; most of our patients are currently able to walk and have partial or total sphincter control.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1578449

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  17 in total

1.  Initial presentation of acute transverse myelitis in systemic lupus erythematosus: demographics, diagnosis, management and comparison to idiopathic cases.

Authors:  Steffan W Schulz; Max Shenin; Amy Mehta; Amal Kebede; Marshall Fluerant; Chris T Derk
Journal:  Rheumatol Int       Date:  2011-07-22       Impact factor: 2.631

2.  Mycophenolate mofetil for lupus related myelopathy.

Authors:  C C Mok; A Mak; C H To
Journal:  Ann Rheum Dis       Date:  2006-07       Impact factor: 19.103

3.  A catastrophic-onset longitudinal myelitis accompanied by bilateral internuclear ophthalmoplegia in a patient with systemic lupus erythematosus.

Authors:  Chang-Woo Rheu; Sang-Il Lee; Wan-Hee Yoo
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

4.  Dexamethasone megadoses stabilize rat liver lysosomal membranes by non-genomic and genomic effects.

Authors:  B Hinz; R Hirschelmann
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

Review 5.  Systemic lupus erythematosus--disease management.

Authors:  M F Gourley
Journal:  Springer Semin Immunopathol       Date:  1994

6.  Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus.

Authors:  L Barile-Fabris; R Ariza-Andraca; L Olguín-Ortega; L J Jara; A Fraga-Mouret; J M Miranda-Limón; J Fuentes de la Mata; P Clark; F Vargas; J Alocer-Varela
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103

7.  Lupus transverse myelopathy: better outcome with early recognition and aggressive high-dose intravenous corticosteroid pulse treatment.

Authors:  V Harisdangkul; D Doorenbos; S H Subramony
Journal:  J Neurol       Date:  1995-05       Impact factor: 4.849

8.  Evaluation of the effects of methylprednisolone pulse therapy in patients with systemic lupus erythematosus with brain involvement by Tc-99m HMPAO brain SPECT.

Authors:  S S Sun; W S Huang; J J H Chen; C P Chang; C H Kao; J J Wang
Journal:  Eur Radiol       Date:  2003-12-09       Impact factor: 5.315

9.  Usefulness of Tc-99m ECD brain SPECT to evaluate the effects of methylprednisolone pulse therapy in lupus erythematosus with brain involvement: a preliminary report.

Authors:  F Y Liu; W S Huang; C H Kao; R F Yen; J J Wang; S T Ho
Journal:  Rheumatol Int       Date:  2003-01-30       Impact factor: 2.631

10.  Central nervous system lupus: concomitant occurrence of myelopathy and cognitive dysfunction.

Authors:  H D Stahl; T H Ettlin; A Plohmann; E W Radü; J Müller-Brand; U Steiger; A Tyndall
Journal:  Clin Rheumatol       Date:  1994-06       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.